Objective: To explore the effect of Shuxuening Injection combined with uricillin in the treatment of mild to moderate acute thrombotic cerebral infarction. Method: 130 patients with mild to moderate acute thrombotic cerebral infarction admitted to our hospital from January 2024 to May 2025 were selected as the research subjects. The patients were divided into the control group and the observation group by random number table method, with 65 cases in each group. The control group received additional treatment with Urinary Kallidinogenase, while the observation group received treatment with Shuxuening injection in addition to the control group. The hemorheology (plasma fibrinogen, plasma viscosity, hematocrit), neurological function [National Institutes of Health Stroke Scale (NIHSS) score, serum myelin basic protein (MBP), neuron-specific enolase (NSE)], thromboxen B2 (TXB2), C-reactive protein (CRP), and adverse reactions of the two groups were analyzed and compared. Results: After treatment, the plasma fibrinogen, plasma viscosity, and various hemorheological indicators of red blood cells in both groups were significantly lower than those before treatment, and the various hemorheological indicators in the observation group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of TXB2 and CRP in both groups were significantly lower than those before treatment, and the serum levels of TXB2 and CRP in the observation group were significantly lower than those in the control group (P < 0.05). After treatment, the NIHSS scores, serum MBP and NSE levels of both groups were significantly lower than those before treatment, and the NIHSS scores, serum MBP and NSE levels of the observation group were significantly lower than those of the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Shuxuening Injection combined with Urinary Kallidinogenase in the treatment of mild to moderate acute thrombotic cerebral infarction can promote the repair of neurological function in patients, regulate hemorheology, reduce the levels of inflammatory factors, and has good safety.